免疫功能低下患者持续性 SARS-CoV-2 感染期间的病毒群体异质性和突变模式波动。
Viral Population Heterogeneity and Fluctuating Mutational Pattern during a Persistent SARS-CoV-2 Infection in an Immunocompromised Patient.
机构信息
Unit of Microbiology, The Greater Romagna Area Hub Laboratory, 47522 Cesena, Italy.
Department of Experimental, Diagnostic and Specialty Medicine (DIMES)-Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy.
出版信息
Viruses. 2023 Jan 19;15(2):291. doi: 10.3390/v15020291.
Literature offers plenty of cases of immunocompromised patients, who develop chronic and severe SARS-CoV-2 infections. The aim of this study is to provide further insight into SARS-CoV-2 evolutionary dynamic taking into exam a subject suffering from follicular lymphoma, who developed a persistent infection for over 7 months. Eight nasopharyngeal swabs were obtained, and were analyses by qRT-PCR for diagnostic purposes. All of them were considered eligible (Ct < 30) for NGS sequencing. Sequence analysis showed that all sequences matched the B.1.617.2 AY.122 lineage, but they differed by few mutations identifying three genetically similar subpopulations, which evolved during the course of infection, demonstrating that prolonged replication is paralleled with intra-host virus evolution. These evidences support the hypothesis that SARS-CoV-2 adaptive capacities are able to shape a heterogeneous viral population in the context of immunocompromised patients. Spill-over of viral variants with enhanced transmissibility or immune escape capacities from these subjects is plausible.
文献中有大量免疫功能低下的患者发展为慢性和严重的 SARS-CoV-2 感染的案例。本研究旨在通过对一名患有滤泡性淋巴瘤的患者进行研究,进一步了解 SARS-CoV-2 的进化动态,该患者持续感染超过 7 个月。我们共采集了 8 份鼻咽拭子,并用 qRT-PCR 进行诊断分析。所有样本的 Ct 值均小于 30,均适合进行 NGS 测序。序列分析表明,所有序列均与 B.1.617.2 AY.122 谱系相匹配,但存在一些突变,可将其分为三个遗传上相似的亚群,这些亚群在感染过程中进化,表明长时间复制与病毒在宿主内进化平行。这些证据支持了这样一种假设,即 SARS-CoV-2 的适应能力能够在免疫功能低下的患者中形成异质性的病毒群体。这些患者体内具有更高传染性或免疫逃逸能力的病毒变异株溢出是合理的。
相似文献
Int J Infect Dis. 2022-9
Microbiol Spectr. 2022-6-29
引用本文的文献
本文引用的文献
Virus Evol. 2022-8-26
Infect Drug Resist. 2022-4-15
Evol Med Public Health. 2022-3-29
Cancer Discov. 2022-1
Nat Commun. 2021-10-20